The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection

HIV Medicine

Volumn 16, Issue 10, 2015, Pages 608-619

  O'Halloran, J A ^a   Dunne, E ^b   Gurwith, M M P ^a   Lambert, J J S ^a   Sheehan, G J ^a   Feeney, E R ^a   Pozniak, A ^c   Reiss, P ^d   Kenny, D ^b   Mallon, P W G ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cardiovascular disease; Endothelial dysfunction; HIV; Monocyte activation; Platelet function

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CD14 ANTIGEN; CD163 ANTIGEN; CD40 LIGAND; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; GLYCOPROTEIN VI; INTERCELLULAR ADHESION MOLECULE 1; LOPINAVIR; PADGEM PROTEIN; RILPIVIRINE; SOLUBLE CD14 ANTIGEN; SOLUBLE CD163 ANTIGEN; SOLUBLE CD40 LIGAND; SOLUBLE GLYCOPROTEIN VI; SOLUBLE P SELECTIN; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; VASCULAR ENDOTHELIUM; ADVERSE EFFECTS; BLOOD; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOCYTE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MONOCYTES;

EID: 84945476402     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12270     Document Type: Article

References (51)

1. Rodger AJ, Lodwick R, Schechter M etal. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27: 973-979.
2. O'Halloran JASC, Mallon PWG. Dyslipidemia, atherosclerosis and cardiovascular disease: an increasingly important triad in an aging population living with HIV. Future Virol 2013; 8: 1021-1034.
3. Zanni MV, Schouten J, Grinspoon SK, Reiss P. Risk of coronary heart disease in patients with HIV infection. Nat Rev Cardiol 2014; 11: 728-741.
4. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011; 32: 945-951.
5. El-Sadr WM, Grund B, Neuhaus J etal. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149: 289-299.
6. Mayne E, Funderburg NT, Sieg SF etal. Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr 2012; 59: 340-346.
7. Satchell CS, Cotter AG, O'Connor EF etal. Platelet function and HIV: a case-control study. AIDS 2010; 24: 649-657.
8. Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166-2171.
9. Singh MV, Davidson DC, Kiebala M, Maggirwar SB. Detection of circulating platelet-monocyte complexes in persons infected with human immunodeficiency virus type-1. J Virol Methods 2012; 181: 170-176.
10. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-2179.
11. Bou Khzam L, Boulahya R, Abou-Saleh H, Hachem A, Zaid Y, Merhi Y. Soluble CD40 ligand stimulates the pro-angiogenic function of peripheral blood angiogenic outgrowth cells via increased release of matrix metalloproteinase-9. PLoS ONE 2013; 8: e84289.
12. Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med 2011; 43: 331-340.
13. Al-Tamimi M, Tan CW, Qiao J etal. Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels. Blood 2012; 119: 4311-4320.
14. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000; 7: 223-242.
15. Solages A, Vita JA, Thornton DJ etal. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42: 1325-1332.
16. Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and platelet function alterations in HIV-infected patients. Thromb Res 2012; 129: 301-308.
17. Ross AC, Rizk N, O'Riordan MA etal. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49: 1119-1127.
18. Gross MD, Bielinski SJ, Suarez-Lopez JR etal. Circulating soluble intercellular adhesion molecule 1 and subclinical atherosclerosis: the Coronary Artery Risk Development in Young Adults Study. Clin Chem 2012; 58: 411-420.
19. Hwang SJ, Ballantyne CM, Sharrett AR etal. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-4225.
20. Malik I, Danesh J, Whincup P etal. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001; 358: 971-976.
21. Alsheikh-Ali AA, Kitsios GD, Balk EM, Lau J, Ip S. The vulnerable atherosclerotic plaque: scope of the literature. Ann Intern Med 2010; 153: 387-395.
22. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013; 339: 161-166.
23. Fitch KV, Srinivasa S, Abbara S etal. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208: 1737-1746.
24. Burdo TH, Lo J, Abbara S etal. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204: 1227-1236.
25. Subramanian S, Tawakol A, Burdo TH etal. Arterial inflammation in patients with HIV. JAMA 2012; 308: 379-386.
26. Longenecker CT, Jiang Y, Orringer CE etal. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014; 28: 969-977.
27. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005; 11: 225-229.
28. Brenchley JM, Price DA, Schacker TW etal. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.
29. Vujkovic-Cvijin I, Dunham RM, Iwai S etal. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5: 193ra91.
30. Hilgendorf I, Swirski FK. Making a difference: monocyte heterogeneity in cardiovascular disease. Curr Atheroscler Rep 2012; 14: 450-459.
31. Zanni MV, Grinspoon SK. HIV-specific immune dysregulation and atherosclerosis. Curr HIV/AIDS Rep 2012; 9: 200-205.
32. Burdo TH, Lentz MR, Autissier P etal. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 2011; 204: 154-163.
33. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206: 1558-1567.
34. Sandler NG, Wand H, Roque A etal. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790.
35. Nockher WA, Bergmann L, Scherberich JE. Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin Exp Immunol 1994; 98: 369-374.
36. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 2000; 67: 97-103.
37. Aristoteli LP, Moller HJ, Bailey B, Moestrup SK, Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006; 184: 342-347.
38. Moreno JA, Ortega-Gomez A, Delbosc S etal. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis. Eur Heart J 2012; 33: 252-263.
39. Hattab S, Guihot A, Guiguet M etal. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. BMC Infect Dis 2014; 14: 122.
40. Mendez-Lagares G, Romero-Sanchez MC, Ruiz-Mateos E etal. Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. J Infect Dis 2013; 207: 1221-1225.
41. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005; 352: 15-35.
42. Adriaanse MP, Tack GJ, Passos VL etal. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Clin Chim Acta 2013; 37: 482-490.
43. Hunt PW, Sinclair E, Rodriguez B etal. Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. J Infect Dis 2014; 210: 1228-1238.
44. O'Brien M, Montenont E, Hu L etal. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr 2013; 63: 280-288.
45. Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G. Platelet-leukocyte interactions in thrombosis. Thromb Res 2012; 129: 263-266.
46. Shechter M, Shechter A, Hod H etal. Brachial artery endothelial function predicts platelet function in control subjects and in patients with acute myocardial infarction. Platelets 2012; 23: 202-210.
47. Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J 1998; 12: 79-89.
48. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185: 456-462.
49. Petoumenos K, Reiss P, Ryom L etal. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. HIV Med 2014; 15: 595-603.
50. Group DADS, Friis-Moller N, Reiss P etal. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
51. Group DADS, Sabin CA, Worm SW etal. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-1426.